RecruitingPhase 4NCT06495593

Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis

Identifying Ocrelizumab-resistant Lymphocytes in Lymphoid Tissue in Multiple Sclerosis

Sponsor

University of California, San Francisco

Enrollment

5 participants

Start Date

Feb 4, 2025

Study Type

INTERVENTIONAL

Conditions

Multiple Sclerosis, Relapsing-Remitting

Summary

B cell-depleting therapies, such as ocrelizumab, are among the most effective medications currently available for the treatment of multiple sclerosis (MS). This suggests that B cells play a very important role in MS. While B cells are rapidly eliminated from the blood of patients treated with medications like ocrelizumab, little is known about how effectively B cells are eliminated from lymph nodes, which are important sites of B cell activation. This study is being conducted to determine to what extent B cells are targeted in lymph nodes following ocrelizumab treatment, which may have important consequences for long-term MS outcomes.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at how ocrelizumab (a B-cell depleting drug used in multiple sclerosis) changes immune cell activity in the lymph nodes, to better understand how it protects the brain and nervous system. **You may be eligible if...** - You have been diagnosed with relapsing-remitting MS (EDSS disability score 0–5.5) - Your neurologist has independently decided that ocrelizumab is the right treatment for you - You have never received a disease-modifying therapy for MS before - Your MS symptoms have been present for less than 15 years (or less than 15 years if your disability score is above 5.0) **You may NOT be eligible if...** - You have already been treated with another MS therapy - You have active severe infections or immune disorders - You are pregnant or planning to become pregnant - You have significant other health conditions that might interfere Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.